Bull World Health Organ. 1994;72(3):341-52.
Cystic fibrosis is one of the commonest genetic diseases among Caucasians and represents an important cause of suffering and death among children and adults. In the past two decades marked prolongation of the life of patients with cystic fibrosis has been achieved as the result of improved case-finding and an extensive regimen of therapies. More recently, a variety of new approaches to therapy have been developed or proposed as the result of advances in cell physiology and molecular biology. This article summarizes the presentations and discussions made at a joint WHO/ICF(M)A (International Cystic Fibrosis (Mucoviscidosis) Association) meeting, held in Washington, DC, on 14 October 1992, and reviews the current status of possible therapies for cystic fibrosis and their implications for treatment in various countries of the world.
囊性纤维化是白种人中最常见的遗传病之一,是儿童和成人痛苦与死亡的一个重要原因。在过去二十年中,由于病例发现的改善和广泛的治疗方案,囊性纤维化患者的寿命显著延长。最近,由于细胞生理学和分子生物学的进展,已经开发或提出了多种新的治疗方法。本文总结了1992年10月14日在华盛顿特区举行的世界卫生组织/国际囊性纤维化(黏液黏稠症)协会联合会议上的报告和讨论,并回顾了囊性纤维化可能治疗方法的现状及其对世界各国治疗的影响。